Page last updated: 2024-11-06

atrinositol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Atrinositol is a synthetic derivative of inositol that has been studied for its potential therapeutic effects in conditions such as Alzheimer's disease, diabetes, and cancer. Its unique chemical structure, with a modified inositol ring, is thought to contribute to its biological activity. Atrinositol has shown promise in preclinical studies by exhibiting anti-inflammatory, neuroprotective, and anti-diabetic effects. However, clinical trials are still ongoing to fully evaluate its safety and efficacy in humans. The compound's ability to interact with key signaling pathways, such as the insulin signaling pathway, makes it a subject of ongoing research. Research aims to further understand its mechanisms of action and explore its potential as a therapeutic agent.'

Cross-References

ID SourceID
PubMed CID65762
CHEMBL ID2106016
SCHEMBL ID636077
MeSH IDM0578269
PubMed CID4129359
SCHEMBL ID180074
MeSH IDM0578269

Synonyms (33)

Synonym
atrinositol [inn]
atrinositol
pp-56
d-myo-inositol 1,2,6-tris(dihydrogen phosphate)
[(1r,2r,4s,5r)-2,3,4-trihydroxy-5,6-diphosphonooxycyclohexyl] dihydrogen phosphate
vyf3049w3n ,
28841-62-5
unii-vyf3049w3n
.alpha.-trinositol
CHEMBL2106016
SCHEMBL636077
GKDKOMAJZATYAY-UOTPTPDRSA-N
d-myo-inositol-1,2,6-triphosphate
d-myo-inositol-1,2,6-tris(hydrogen phosphate)
[(2r,3s,5r,6r)-3,4,5-trihydroxy-2,6-diphosphonooxycyclohexyl]dihydrogenphosphate
d-myo-inositol-1.2.6-triphosphate
GKDKOMAJZATYAY-GCVPSNMTSA-N
Q27292095
(1r,2s,3r,4r,5s,6s)-4,5,6-trihydroxycyclohexane-1,2,3-triyl tris(dihydrogen phosphate)
-trinositol
DTXSID701317926
AKOS040750626
inositol 1,2,6-triphosphate
pp56
(2,3,4-trihydroxy-5,6-diphosphonooxycyclohexyl) dihydrogen phosphate
myo-inositol 1,2,3-trisphosphate
inositol 1,2,3-trisphosphate
FT-0670354
SCHEMBL180074
alpha-trinositol
pp 56
DTXSID00865454
4,5,6-trihydroxycyclohexane-1,2,3-triyl tris[dihydrogen (phosphate)]

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" bolus reduced the entire NPY dose-response curve (0."( D-myo-inositol-1,2,6-trisphosphate is a selective antagonist of neuropeptide Y-induced pressor responses in the pithed rat.
Dahlöf, C; Edvinsson, L; Hedner, T; Sun, XY, 1991
)
0.28
" The augmenting effect of neuropeptide Y at 1 nM on vasoconstriction induced by lower doses of noradrenaline was antagonized by alpha-trinositol (1 microM), producing a shift to the right of the dose-response curve."( Inhibition of neuropeptide Y-induced augmentation of noradrenaline-induced vasoconstriction by D-myo-inositol 1,2,6-trisphosphate in the rat mesenteric arterial bed.
Burnstock, G; Edvinsson, L; Ralevic, V, 1994
)
0.29
" Heart rate did not change in the SHR, whereas it was significantly increased at the highest dosage (400 mg/kg) in the WKY rats."( Cardiovascular effects of alpha-trinositol in spontaneously hypertensive and normotensive Wistar-Kyoto rats.
Edvinsson, L; Hedner, T; Sun, X, 1993
)
0.29
" The pial vessel study demonstrated that PP56 shifted the dose-response curve for the vasoconstrictor effect of NPY with a maximal reduction of 22 +/- 6%."( Examination of the involvement of neuropeptide Y (NPY) in cerebral autoregulation using the novel NPY antagonist PP56.
Edvinsson, L; Goadsby, PJ, 1993
)
0.29
" As a conclusion, no analgesic effect of alpha-trinositol at the dosage used was observed in the postoperative patients studied."( Postoperative recovery after cholecystectomy by minilaparotomy: a randomized double-blind comparison between alpha-trinositol and placebo.
Holmin, T; Landquist, E; Luttropp, HH; Westerling, D, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (115)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.87)18.7374
1990's81 (70.43)18.2507
2000's25 (21.74)29.6817
2010's8 (6.96)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (3.09%)5.53%
Trials0 (0.00%)5.53%
Reviews2 (2.06%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other92 (94.85%)84.16%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]